Instil Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Instil Bio, Inc. on May 28, 2025. The Company is an emerging growth company incorporated in Delaware, with its common stock (TIL) trading on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Stockholder participation was high, with 5,871,933 shares (approximately 89.5% of the 6,558,927 outstanding shares) present or represented by proxy. Two proposals were voted upon:
- Proposal 1 (Election of Directors): Stockholders elected Bronson Crouch as a Class I director. He received 4,662,952 votes "For," 281,585 votes "Withheld," and there were 927,396 broker non-votes.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The vote was 5,862,181 "For," 8,649 "Against," and 1,103 "Abstentions."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves strictly as a record of the Annual Meeting outcomes.
Key Facts for Investor Verification
- Verify the full composition of the Board of Directors following the election of Bronson Crouch.
- Confirm the engagement terms and scope of work with Deloitte & Touche LLP for the 2025 fiscal year.
- Review the definitive proxy statement (Schedule 14A) filed on April 14, 2025, for detailed background on the proposals.
- Note the high level of stockholder engagement (89.5% participation) at the Annual Meeting.